IgA Nephropathy Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies – Omeros, Chinook Therapeutics, Travere Therapeutics, Novartis Pharmaceuticals

March 08 19:37 2023
IgA Nephropathy Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies - Omeros, Chinook Therapeutics, Travere Therapeutics, Novartis Pharmaceuticals
The IgA Nephropathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage IgA Nephropathy pipeline products will significantly revolutionize the IgA Nephropathy market dynamics.

DelveInsight’s “IgA Nephropathy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the IgA Nephropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The IgA Nephropathy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 


To Know in detail about the IgA Nephropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; IgA Nephropathy Market Insights


IgA Nephropathy Overview

IgA Nephropathy (IgAN) is an autoimmune disease that attacks the kidneys. It affects blood filtration in the small blood vessels of the kidneys. IgAN occurs when an abnormal protein damages the filtering unit (glomerulus) inside the kidneys.


Some of the key facts of the IgA Nephropathy Market Report:  

  • The IgA Nephropathy market size valued at approximately USD 180 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032) 
  • IgA Nephropathy is the most common glomerular disease worldwide but varies largely geographically 
  • The total prevalent cases of IgA nephropathy were the highest in the United States, with approximately 134,000 cases, and lowest in Spain with around 20,000 
  • In the United States, there were over 60,000 cases of IgA nephropathy in the age group of 45–64 years, which is expected to rise in 2032. 
  • Key IgA Nephropathy Companies: Omeros, Chinook Therapeutics, Travere Therapeutics, Novartis Pharmaceuticals, Otsuka Pharmaceutical, and others 
  • Key IgA Nephropathy Therapies: Narsoplimab, Atrasentan, Sparsentan, Iptacopan, Sibeprenlimab, and others
  • The IgA nephropathy epidemiology based on gender analyzed that IgA Nephropathy is more prominent in males in comparison to females. Incidence of IgA nephropathy occurs in men around two times more than females worldwide 


Get a Free sample for the IgA Nephropathy Market Report – 



Key benefits of the IgA Nephropathy Market report:

  1. IgA Nephropathy market report covers a descriptive overview and comprehensive insight of the IgA Nephropathy Epidemiology and IgA Nephropathy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The IgA Nephropathy market report provides insights on the current and emerging therapies.
  3. IgA Nephropathy market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The IgA Nephropathy market report offers an edge that will help develop business strategies by understanding trends shaping and driving the IgA Nephropathy market.


Download the report to understand which factors are driving IgA Nephropathy epidemiology trends @ IgA Nephropathy Epidemiological Insights 


IgA Nephropathy Market  

The dynamics of the IgA Nephropathy market are anticipated to change in the coming years owing to the expected launch of emerging therapies such and others during the forecasted period 2019-2032. 

“Greater efforts should be made to diagnose IgA Nephropathy earlier in individuals who manifest persistent microhematuria and/or mild proteinuria and to introduce less stringent indications for kidney biopsies. This preventive approach, followed by early therapy, may reduce the global burden of end-stage kidney disease caused by IgA Nephropathy.” 


IgA Nephropathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.


IgA Nephropathy Epidemiology Segmentation:

The IgA Nephropathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of IgA Nephropathy
  • Prevalent Cases of IgA Nephropathy by severity
  • Gender-specific Prevalence of IgA Nephropathy
  • Diagnosed Cases of Episodic and Chronic IgA Nephropathy


IgA Nephropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the IgA Nephropathy market or expected to get launched during the study period. The analysis covers IgA Nephropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the IgA Nephropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.


Discover more about therapies set to grab major IgA Nephropathy market share @ IgA Nephropathy market forecast 


IgA Nephropathy Therapies and Key Companies

  • Narsoplimab: Omeros
  • Atrasentan: Chinook Therapeutics
  • Sparsentan: Travere Therapeutics
  • Iptacopan: Novartis Pharmaceuticals
  • Sibeprenlimab: Otsuka Pharmaceutical


IgA Nephropathy Market Drivers

  • Robust pipeline of emerging IgA Nephropathy therapies. 
  • Scientific advances and identification of novel biomarkers for disease diagnosis and monitoring of disease progression


Scope of the IgA Nephropathy Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key IgA Nephropathy Companies: Omeros, Chinook Therapeutics, Travere Therapeutics, Novartis Pharmaceuticals, Otsuka Pharmaceutical, and others
  • Key IgA Nephropathy Therapies: Narsoplimab, Atrasentan, Sparsentan, Iptacopan, Sibeprenlimab, and others
  • IgA Nephropathy Therapeutic Assessment: IgA Nephropathy current marketed and IgA Nephropathy emerging therapies
  • IgA Nephropathy Market Dynamics: IgA Nephropathy market drivers and IgA Nephropathy market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • IgA Nephropathy Unmet Needs, KOL’s views, Analyst’s views, IgA Nephropathy Market Access and Reimbursement 


IgA Nephropathy Market Opportunities

  • Future development of potential biomarkers may improve screening and early detection of IgA Nephropathy
  • Development of novel therapeutic targets: a market space with a huge patient population and no approved IgA Nephropathy treatments


Table of Contents 

1. IgA Nephropathy Market Report Introduction

2. Executive Summary for IgA Nephropathy

3. SWOT analysis of IgA Nephropathy

4. IgA Nephropathy Patient Share (%) Overview at a Glance

5. IgA Nephropathy Market Overview at a Glance

6. IgA Nephropathy Disease Background and Overview

7. IgA Nephropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of IgA Nephropathy 

9. IgA Nephropathy Current Treatment and Medical Practices

10. IgA Nephropathy Unmet Needs

11. IgA Nephropathy Emerging Therapies

12. IgA Nephropathy Market Outlook

13. Country-Wise IgA Nephropathy Market Analysis (2019–2032)

14. IgA Nephropathy Market Access and Reimbursement of Therapies

15. IgA Nephropathy Market Drivers

16. IgA Nephropathy Market Barriers

17.  IgA Nephropathy Appendix

18. IgA Nephropathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight


To know more about IgA Nephropathy treatment, visit @ IgA Nephropathy Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis